MetaVia Inc., a clinical-stage biotechnology company, has announced the dosing of the first patient in the 48 mg multiple ascending dose cohort of its Phase 1 clinical trial for DA-1726, a dual oxyntomodulin analog agonist designed for obesity treatment. This trial aims to explore the maximum tolerated dose of DA-1726, which functions as both a glucagon-like peptide-1 receptor and glucagon receptor agonist. Previous data from the 32 mg dose has indicated potential therapeutic benefits, such as dose-dependent weight loss and waist reduction, without inducing hypoglycemia. The drug has also demonstrated favorable cardiovascular safety and tolerability profiles. MetaVia expects to present the top-line data from the 48 mg cohort in the fourth quarter of 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。